Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Ca - sprookjes - yvandenbroek - TriplyDB

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Ca

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Ca

http://www.wikidata.org/entity/Q33247166

about

Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas Temozolomide for high grade glioma Temozolomide for High Grade Glioma Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors The 2007 WHO classification of tumours of the central nervous system Malignant gliomas: old and new systemic treatment approaches Current status of biomarker research in neurology Clinical management of grade III oligodendroglioma Diagnosis and treatment in neuro-oncology: an oncological perspective Recent advancements in multimodality treatment of gliomas Modern brain tumor imaging Oligodendroglioma: pathology, molecular mechanisms and markers Systematic review of supportive care needs in patients with primary malignant brain tumors MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors Neuro-oncology: Five new things.Initial treatment patterns over time for anaplastic oligodendroglial tumors.International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.Angiogenic inhibition in high-grade gliomas: past, present and future.CyberKnife enhanced conventionally fractionated chemoradiation for high grade glioma in close proximity to critical structures.Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.Longitudinal quality of life data: a comparison of continuous and ordinal approaches.BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative.Predictive and prognostic markers in neuro-oncology.Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.Controversies in the adjuvant therapy of high-grade gliomas.Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q.Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI Actionable molecular biomarkers in primary brain tumors.

P2860

Q24194645-D0F768BB-4F44-448C-9668-94CCAB2CFCC0 Q24197645-039AA467-CDA7-4E9A-8D51-35793FCF75E3 Q24241222-479D2AA0-38DE-49EA-B049-477C45C91BA9 Q24242968-2C0A74D6-CF91-4C47-B4A6-3F0977AD5C38 Q24683022-1CC315AD-7C60-453C-B094-248B5D578DBC Q24685772-DD216E3E-1586-443F-B3FB-2B0423E30EAA Q26744387-D03B5A24-7BC6-4EB0-A96C-C7255D969211 Q26744505-7ABE325F-A7E9-49DE-9B28-EF97F026070D Q26801254-001995EE-4DE5-4825-BFA3-5B9974A666B7 Q26860696-77EBE323-3417-4A16-B26A-EEFEC6DE4263 Q27001724-E9CAE5C9-0873-49A7-8E49-D246C57DBC03 Q27002344-5EAC852B-E382-4607-A6AB-ED816EF41831 Q27002448-5D5F398B-C741-48B6-8050-9445A528A64C Q27012547-D7ABBD4C-6ECB-4CE2-92F6-EA28E23448D4 Q27851529-1C5D4D63-B51C-40FB-8CAA-E5DEC16853FE Q27852494-AD701546-8D35-4724-B5A7-942179AA8D7E Q28383205-F5308F5F-6B10-4288-8E0F-9C6A5D6F43D5 Q30370204-AA17E3D6-EDA7-4C4C-AE6B-818647B2517A Q30415098-00EF6F5B-3A1B-4229-9EDC-A715C4087F84 Q30419123-AF27B524-A07C-4F9B-87AA-59E0C193FB34 Q30426724-71745BCD-F4BB-4C60-BDF9-6E743B77C45C Q30444816-F2582F97-8253-42DD-8A63-B28108AB2FDE Q30455596-26AA16BE-AD90-44C9-8DF4-EBA6C4226633 Q30480933-A2DA1D0C-045C-40DF-9724-B9DFDB4A2684 Q30542081-2E543E74-9E5B-41E6-AF9C-1D64CB23AA96 Q30829260-C3993E4A-8AB6-433A-9C02-E1CBE037B90A Q31002780-640D42D4-9BBB-4626-BB61-34CC4086CED6 Q31034367-5648D2BA-0E90-4F6A-944A-5D297C76B259 Q33311133-F3379C03-B0EB-470F-8BA8-27C00EF620DE Q33387577-41B7EE50-792A-4132-BF40-EF7CCBC1220D Q33394265-D25D30D1-F5B4-4AA7-8B32-450FBA986511 Q33410196-06150356-2D42-43A7-8D6A-17443B2B5810 Q33447142-FADF0978-BAB2-4FA0-AC2C-73D095C18400 Q33519196-0ACBA3CF-33E6-45E7-BF8D-D9D67C4CE3F4 Q33532354-F7C9887B-84D4-4009-B3E9-71FEA8B67B37 Q33636469-AAD47EE8-A078-4A49-AAB1-944616F2743D Q33638116-EAA49E52-74FC-4716-9CA2-77075BD4AFA8 Q33649896-C8E77D72-185B-466F-B031-1E068E89AC2E Q33733375-127D4123-F919-4396-8516-76A51E374430 Q33772355-07655369-D0BD-47AE-AA73-8851EFD61E33

P2860

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Ca

http://www.wikidata.org/entity/Q33247166

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Adjuvant procarbazine, lomusti ...... r Research and Treatment of Ca

@ast

Adjuvant procarbazine, lomusti ...... r Research and Treatment of Ca

@en

type

label

Adjuvant procarbazine, lomusti ...... r Research and Treatment of Ca

@ast

Adjuvant procarbazine, lomusti ...... r Research and Treatment of Ca

@en

prefLabel

Adjuvant procarbazine, lomusti ...... r Research and Treatment of Ca

@ast

Adjuvant procarbazine, lomusti ...... r Research and Treatment of Ca

@en

P1433

Q33247166-E4A14E99-5CFE-422D-85C6-2D6382C9B5B4

P1476

Q33247166-BDB4A735-9F87-4505-97B2-43D5659E5309

P2093

Q33247166-016B01F2-58E3-4432-936C-1D348DCF3446

Q33247166-02385AC6-2555-4B94-B3BE-5097158E64C5

Q33247166-0524A3CF-FF29-43E0-96D3-D154E09AE3E7

Q33247166-2BDD7CDA-91B9-4A3F-8019-F5CAE3002D04

Q33247166-5512D2C1-64CC-4AF0-A395-1BBB3C69516F

Q33247166-869A01ED-B23C-4EE6-8841-E13E8B82DC14

Q33247166-91E8CE7D-6D37-49F1-B535-0C07C64C19B6

Q33247166-B9167A1C-3917-4199-8340-745D157D53E9

Q33247166-BB1A15A5-D621-48EC-826F-CFBFB2A617D9

Q33247166-BD304AD5-B816-468F-B422-2D2E707959E2

P304

Q33247166-506DF98B-1E34-4448-8C12-CB184537658E

P31

Q33247166-B65BA2FA-146B-4BDB-803E-73F1211500C1

P356

Q33247166-4B68FF35-01EF-424D-86D0-4178372B6027

P407

Q33247166-E76809C4-5F57-45D2-B8E0-3595166492A4

P433

Q33247166-B07EF763-4140-4311-9026-86583E78177A

P478

Q33247166-2F738E2C-FB32-4F7F-8961-537514A9C216

P50

Q33247166-59C319CF-9A78-4986-8944-A643C9AA0BE8

Q33247166-776D60E8-87A5-4069-9105-A7928345E929

P577

Q33247166-F3710FE0-523C-4065-8496-2101F8B3972B

P698

Q33247166-012E0104-DE47-4A40-854A-84DE5AFB974B

P921

Q33247166-40B2B8D8-5E50-4299-B73F-6B21D677176C

P356

JCO.2005.04.6078

P1433

Journal of Clinical Oncology

P1476

Adjuvant procarbazine, lomusti ...... ment of Cancer phase III trial

@en

P2093

Anouk Allgeier

http://www.w3.org/2001/XMLSchema#string

Antoine F Carpentier

http://www.w3.org/2001/XMLSchema#string

Cees C Tijssen

http://www.w3.org/2001/XMLSchema#string

Charles J Vecht

http://www.w3.org/2001/XMLSchema#string

Denis Lacombe

http://www.w3.org/2001/XMLSchema#string

Hanny Haaxma-Reiche

http://www.w3.org/2001/XMLSchema#string

Hans J J A Bernsen

http://www.w3.org/2001/XMLSchema#string

Johannes M Kros

http://www.w3.org/2001/XMLSchema#string

Laslo Sipos

http://www.w3.org/2001/XMLSchema#string

Marc Frenay

http://www.w3.org/2001/XMLSchema#string

P304

2715-2722

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.04.6078

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Alba A. Brandes

Martin J van den Bent

P577

2006-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16782911

http://www.w3.org/2001/XMLSchema#string

P921

oligodendroglioma